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Xinmu Zhang and Ruitang Deng
Abstract
Bile acids are synthesized in the liver and tightly regulated through the enterohe-
patic circulation. Recent studies reveal that bile acids serve as hormone-like signal-
ing molecules to activate nuclear receptors, notably farnesoid X receptor (FXR), 
regulating metabolic homeostasis of bile acids, cholesterol, lipids, and glucose. 
A connection between bile acids and nonalcoholic fatty liver disease (NAFLD) 
has long been recognized. Although inconsistent or even contradictory results 
are reported, a large body of evidence from clinical as well as preclinical studies 
demonstrates that bile acid homeostasis is disrupted in patients with NAFLD. The 
bile acid dysregulation gets worsening as NAFLD progresses from early stage simple 
steatosis to late stage nonalcoholic steatohepatitis (NASH) and NASH with fibrosis. 
As the risk factors for NAFLD, obesity and insulin resistance, which are often 
associated with NAFLD, contribute to the dysregulation of bile acids in patients 
with NAFLD. Total serum and fecal bile acid concentrations are mostly elevated in 
patients with NAFLD as a result of increased bile acid synthesis, elevated hepatic 
bile acids, and upregulation of bile acid transporters. The two negative feedback 
regulatory pathways for bile acid synthesis, FXR/SHP (small heterodimer partner) 
and fibroblast growth factor-19 (FGF19)/FGF receptor-4 (FGFR4), are impaired in 
patients with NAFLD.
Keywords: NAFLD, steatosis, fatty liver, NASH, bile acids, FXR, bile acid synthesis, 
enterohepatic circulation, bile acid transporters, FGF19
1. Introduction
Nonalcoholic fatty liver disease (NAFLD) is the most prevalent form of chronic 
liver disease worldwide. It affects about 30% of the population in the United 
States [1, 2] and 10% of adolescents and children [3, 4]. NAFLD is a spectrum of 
metabolic disorders starting with simple steatosis characterized with excessive 
accumulation of triglycerides in the hepatocytes, progressing to nonalcoholic 
steatohepatitis (NASH) characterized with inflammation, to fibrosis and cirrhosis, 
and eventually to liver failure and hepatocellular carcinoma (HCC) [5–7]. Obesity 
and insulin resistance or diabetes are the most prevalent risk factors for develop-
ment of NAFLD [8–13].
Bile acids are the metabolites of cholesterol and synthesized in the liver. It is 
well known that bile acids act as biological detergents to solubilize cholesterol 
and lipids in the bile and intestine, play important roles in cholesterol and lipid 
absorption and transport. Recent studies have revealed that bile acids can serve 
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as hormone-like signaling molecules to activate several nuclear receptors, notably 
the farnesoid X receptor (FXR) [14, 15]. The bile acids/FXR signaling plays critical 
roles in regulating a myriad of metabolic homeostasis including bile acids, choles-
terol, lipids, and glucose [16–19], as well as inflammation/immunity [20–24] and 
liver regeneration [25–27].
Under physiological condition, bile acid homeostasis is maintained through 
multiple negative feedback loops for bile acid synthesis [18, 28–30] and a tightly 
regulated enterohepatic circulation of bile acids [31–34]. Since liver is the organ for 
bile acid synthesis and metabolism and biliary excretion of bile acids is the limit-
ing step for the enterohepatic circulation [35, 36], impairment of liver function as 
a result of various liver disorders leads to dysregulation of bile acids. Indeed, the 
measurement of bile acids is considered a biomarker of liver function and serves as 
an indicator of hepatobiliary impairment or diseases [37–41]. On the other hand, 
excessive accumulation of bile acids in the liver causes liver damages by multiple 
mechanisms including disrupting the integrity of cell membranes through their 
detergent property [42–44], causing mitochondrial stress and promoting the 
generation of reactive oxygen species [45–48], and inducing endoplasmic reticu-
lum stress [49–51] and inflammatory responses [52–54], resulting in cell death via 
apoptosis and/or necrosis [55–58].
Because of the reciprocal effects between liver damage and bile acid dysregula-
tion, it is often difficult, if not impossible, to determine the cause-and-effect 
relation between liver damage and bile acid dysregulation for many liver disorders. 
In one hand, liver damage causes bile acid dysregulation. On the other hand, 
bile acid dysregulation potentially causes liver damage. The connection between 
NAFLD and bile acid dysregulation has long been recognized and reported [59–67]. 
It is well established that liver function is compromised in patients with NAFLD, 
especially advanced stages of NAFLD, such as NASH and NASH-associated fibrosis 
and cirrhosis, due to pathological and structural damages to the liver. Research 
interests and emphasis are recently condensed on investigating the contribution of 
bile acid dysregulation to the pathogenesis of NAFLD and developing therapeutic 
interventions for NAFLD by manipulating the bile acid signaling pathway [66–73]. 
However, the outcomes of clinical trials targeting bile acid signaling using ursode-
oxycholic acid (UDCA) and obeticholic acid (OCA) to treat NASH patients are not 
very encouraging [74–79], indicating that our understanding on the relationship 
between bile acids and NAFLD is not complete or even may be misinterpreted.
Taken together, the link between bile acids and NAFLD has been firmly estab-
lished. However, certain fundamental questions remain to be answered. How bile 
acid homeostasis is disrupted in patients with NAFLD? Whether dysregulation 
of bile acids is one of the manifestations of NAFLD or actually contributes to the 
development and/or progression of NAFLD? It only becomes possible to develop 
rationalized approaches to treat patients with NAFLD until those fundamental 
questions are fully addressed. In this chapter, the effects of NAFLD on bile acid 
homeostasis are reviewed and discussed.
2. Altered bile acid profiles in subjects with NAFLD
In human, cholic acids (CAs) and chenodeoxycholic acid (CDCA) are two pri-
mary bile acids synthesized in the liver and account for majority of bile acids in the 
bile acid pool. Upon excretion into intestine, primary bile acids can be converted 
into secondary bile acids by gut bacteria. Specifically, CA is converted into deoxy-
cholic acid (DCA), while CDCA is converted into lithocholic acid (LCA) or UDCA 
in the intestine by dehydroxylation [80, 81] or 7β epimerization [82–84]. Majority 
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of primary and secondary bile acids are conjugated by either glycine or taurine 
in the liver, generating glycine- or taurine-conjugated bile acids [80, 81]. Under 
physiological conditions, total bile acid levels, as well as the composition of the 
bile acid pool, are regulated and maintained. However, under various pathological 
conditions, especially liver disorders, the bile acid pool size or total bile acids and 
bile acid pool compositions are altered. A large number of clinical and preclinical 
studies have revealed that bile acid profiles are altered in patients with NAFLD and 
rodent NAFLD models.
2.1 Altered bile acid profiles in patients with NAFLD
2.1.1 Serum bile acids
Under the physiological condition, serum bile acid concentrations are much 
lower than those in the enterohepatic system. However, when the enterohepatic 
cycling of bile acids is compromised due to hepatic injuries or intestine disorders, 
bile acids are spilled into the blood circulation system, altering serum bile acid con-
centrations, as well as compositions. Bile acid profiling in healthy populations has 
revealed that serum bile acid concentrations and compositions are age dependent 
[85]. Therefore, the serum bile acid profiles in adult and children with NAFLD are 
separately described in the following sections.
2.1.1.1 Serum bile acid profiling in adults with NAFLD
Currently, there are total nine clinical studies investigating serum bile acid levels 
and compositions in adults with NAFLD. In study 1 with 25 healthy subjects, 11 
patients with steatosis, and 24 patients with NASH, it was found that serum bile 
acid profiles after overnight fasting were significantly altered in both steatotic and 
NASH patients, especially in patients with NASH [86]. The most prominent altera-
tion is the markedly increased conjugated CA concentration. Taurine-conjugated 
CAs (TCAs) were elevated 4- and 2.2-fold, while glycine-conjugated CAs (GCAs) 
were increased 4.3- and 3.1-fold in patients with NASH and steatosis, respectively. 
Similarly, GCDCA levels were also elevated by 2- and 2.4-fold in patients with 
NASH and steatosis, respectively. Other bile acid species, including CA, GDCA, 
TDCA, and TCDCA, exhibited a trend of increase but their levels did not reach a 
statistical significance. It should be noted that patients with steatosis or NASH had 
significantly elevated insulin levels and exhibited insulin resistance, although the 
blood glucose levels were within the normal range. The patients, especially those 
with NASH, also had elevated serum alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels, indicating liver damage in those patients.
In study 2 with 15 healthy controls and 7 NASH patients, both fasting and 
postprandial bile acids were altered [87]. Total fasting serum bile acid levels were 
increase by more than twofold. Such increases in total bile acids are mainly due to 
significantly increased conjugated bile acids with both glycine and taurine, while 
unconjugated bile acids were not significantly altered. Both primary (CDCA and 
CA and their conjugated) and secondary (DCA and LCA and their conjugated) bile 
acids were markedly elevated. Similarly, postprandial serum bile acid levels were 
also markedly increased in patients with NASH, including total, conjugated and 
unconjugated, primary, and secondary bile acids. However, the relative ratios or the 
compositions of the serum bile acid pools were not significantly altered in both fast-
ing and postprandial levels. Significant elevations in individual bile acids including 
DCA, GCA, GCDCA, and TCA were also noted. Other bile acid species including 
CA and CDCA were either not altered or slightly increased without reaching a 
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statistical significance. Patients with NASH had significantly elevated alkaline 
phosphatase (ALP), ALT, insulin, and homeostatic model assessment (HOMA) 
levels accompanied with significantly higher fast blood glucose levels when com-
pared to the control subjects.
In study 3 with 24 healthy subjects, 25 steatotic, and 37 NASH patients, plasma 
bile acids after fasting were measured [88]. Total plasma primary bile acids (CA and 
CDCA) were gradually increased from controls to steatotic to NASH patients. On 
the contrary, total secondary bile acids (DCA and LCA) were gradually decreased 
from controls to steatotic to NASH patients. The increases in primary bile acids are 
mainly resulted from elevation of the conjugated bile acids, while the unconju-
gated primary bile acids (CA and CDCA) were comparable to those in the control 
subjects. Comparison between the two NAFLD groups, total conjugated CA and 
conjugated primary bile acids, was significantly higher in subjects with NASH 
compared to steatotic subjects. In addition, the compositions of the primary bile 
acid pools were also changed with significant increase in the ratios of total primary 
CA to CDCA, regardless of the status of diabetes. Although total secondary bile 
acids were lower in NASH patients, most of the individual secondary bile acids 
including GDAC, TDCA, TLCA, and GLCA were comparable among the three 
groups except for unconjugated DCA, which was significantly higher in NASH 
patients. Unconjugated UDCA levels were comparable among the three groups, 
while conjugated UDCA was significantly higher in NASH patients compared to 
steatotic and control subjects. It should be mentioned that AST and ALT levels were 
significantly elevated in both steatotic and NASH patients, indicating hepatic injury 
under the steatotic and NASH conditions. In addition, a large percentage of NASH 
patients (62.2%) were diabetic, while 20% of steatotic patients were diabetic with 
only one subject (4.2%) being diabetic in the control group.
In study 4 with 14 healthy controls and 7 patients with NASH, serum total bile 
acids were significantly elevated by 2.5-fold in patients with NASH compared to 
healthy control subjects [89]. Individual bile acids including GCA and TCA were 
markedly increased by 3.1- and 5.7-fold in patients with NASH, respectively. In 
addition, linear regression analysis revealed a significant association between 
NAFLD activity scores (NAS) and fasting total serum bile acid, GCA, and TCA con-
centrations. It should be mentioned that the fasting total bile acids, GCA and TCA 
serum, concentrations in healthy controls in the study were comparable to those 
reported previously for healthy adults [90].
In study 5 with 46 healthy control subjects and 13 patients with NAFLD, serum 
bile acids were dysregulated in patients with NAFLD [38]. Total serum bile acid 
levels were significantly increased by 4.7-fold from 2.8 μM in control subjects to 
13.0 μM in NAFLD patients. Primary and secondary bile acids were elevated by 
3.8- and 1.9-fold, respectively, in NAFLD patients. These increases in total, pri-
mary, and secondary bile acids are mainly due to much higher concentrations of 
conjugated bile acids in NAFLD patients (5.0 μM) than in control subjects (1.2 μM). 
Unconjugated bile acids were also slightly increased from 0.88 μM in control 
subjects to 1.30 μM in NAFLD patients without reaching a statistical significance.
In contrast to most of the previous studies, a recent study 6 with 32 patients with 
NASH and 26 non-NASH controls reported that plasma total, primary, secondary, 
unconjugated, and conjugated bile acids were not significantly different between 
the two groups [91]. The compositions of the plasma bile acid pools were also 
not altered either in patients with NASH when compared to non-NASH subjects. 
However, when the subjects were subcategorized into insulin resistance and insulin 
sensitive groups, significant changes in bile acid profiles were detected. Total serum 
CA (CA + GCA and TCA), unconjugated CA, total CDCA (CDCA + GCDCA + 
TCDCA), unconjugated CDCA, total primary and unconjugated primary, total 
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unconjugated, and non-12α bile acids were all significantly elevated in subjects 
with insulin resistance compared to insulin sensitive subjects. The authors therefore 
concluded that bile acid alterations were associated with insulin resistance but not 
NASH. The study also showed that body mass index (BMI), fasting plasma insulin 
concentrations, and HOMA values positively correlated with plasma CA and CDCA 
levels. It should be mentioned that the BMI and HOMA values were matched 
between the NASH patients and the non-NASH control subjects in this study. The 
average BMI was 40.2 for NASH and 39.4 for non-Nash subjects, indicating that 
both groups are severely obese. The average HOMA was 4.05 for NASH patients and 
3.25 for non-NASH controls, indicating insulin resistance in both groups.
Consistent with the findings from the sixth study, another clinical study 
reported that patients with NAFLD exhibited comparable serum total bile acid 
concentrations to those in healthy control subjects [92]. The study included 16 
healthy controls with an average BMI of 24.2, 14 overweight NAFLD patients 
with BMI of 28.3, and 12 obese NAFLD patients with an average BMI of 35.3. No 
significant alterations in fasting as well as postprandial serum total bile acid levels 
were detected between healthy control subjects and overweight or obese NAFLD 
patients.
In another study with 38 control subjects and 36 NASH patients, limited infor-
mation about the characteristics of the studied subjects was provided and only data 
on three individual bile acid species were reported. The plasma concentrations of 
GCA, TCA, and TCDCA during fasting were significantly elevated in patients with 
NASH compared to control subjects [93]. Consistent with finding from most of the 
studies, another clinical study with 10 healthy controls, 39 steatotic, and 59 NASH 
patients reported that total serum bile acid levels were significantly elevated in 
patients with NAFLD [94].
The findings from six clinical studies, which provide detailed characteristics 
of the studied subjects as well as the corresponding bile acid profiles, are summa-
rized in Table 1. The results from studies 1 to 5 are largely consistent. Serum total, 
primary, and conjugated bile acids were all significantly increased with limited 
changes for unconjugated bile acids. However, the secondary bile acids were sig-
nificantly increased in studies 1, 2, and 5 but decreased in study 3. In contrast to the 
findings from studies 1 to 5, no significant alterations were detected in serum total, 
primary, secondary, conjugated, and unconjugated bile acids in the study 6.
Compared the characteristics of the control and NAFLD subjects, it is noticed 
that the control subjects in study 6 were severely obese with BMI 39.4 ± 5.9, while 
the control subjects in studies 1–5 have normal or close to normal body weights with 
BMI ranging from 24.5 ± 2.6 to 27.3 ± 5.8. The BMI values were matched between 
NAFLD patients and control subjects in study 6 but significantly different in studies 
1–5. Compared with serum bile acid levels in a healthy population [85], the control 
subjects in study 6 had markedly increased total, primary, secondary, conjugated, 
and unconjugated bile acids. The results indicate that obesity or increased BMI is a 
contributing factor to the dysregulation of serum bile acids. Indeed, several studies 
have reported that subjects with overweight or obese had increased serum bile acid 
concentrations [85, 95, 96].
The second characteristic of the studied subjects that is different between 
study 6 and studies 1–5 is the status of insulin resistance in the control subjects. 
The serum insulin levels and HOMA values in study 6 are markedly higher 
than those in the other five studies, suggesting that insulin resistance is a con-
tributing factor for the dysregulation of serum bile acids. Indeed, when all the 
subjects (NAFLD and control patients) in the study 6 were separated by insulin 
resistance status, primary bile acids, unconjugated bile acids, and non-12α bile 
acids, total CA and total CDCA were significantly increased in subjects with 
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insulin resistance compared to insulin sensitive subjects regardless of the status 
of NAFLD. These data strongly suggest that insulin resistance is a contributing 
factor to the dysregulation of bile acids, which is supported by the findings from 
previous studies [95–100].
Features Subjects Study 1 
[87]
Study 2 
[88]
Study 3 [89] Study 4 
[90]
Study 5 
[92]
Study 6 
[93]
Sample 
size
Control 25 15 24 14 46 26
Steatosis 11 25
NASH 24 7 37 7 13 32
Age Control 42.6 ± 9.2 43 ± 12 39.2 ± 12.4 42 ± 13 20–39 40.5 ± 11.7
Steatosis 43.5 ± 10.7 54.6 ± 10.1
NASH 43.6 ± 12.6 48 ± 10 58.0 ± 8.8 48 ± 10 62.5 ± 16.5 41.3 ± 11.9
BMI Control 24.5 ± 2.6 25 ± 2.7 27.3 ± 5.8 26 ± 2.7 <25 39.4 ± 5.9
Steatosis 34.0 ± 4.0 32.6 ± 5.4
NASH 34.8 ± 4.7 32.0 ± 5.2 34.4 ± 4.2 32 ± 5.2 25.5 ± 2.8 40.2 ± 5.8
Insulin Control 7.6 ± 3.1 7.6 ± 2.6 N/A 8.0 ± 3.0 N/A 15.7 ± 9.1
Steatosis 20.6 ± 9.0 N/A
NASH 26.5 ± 14.9 40 ± 27 N/A 40 ± 27 N/A 18.9 ± 11.4
HOMA-IR Control 0.9 ± 0.4 1.6 ± 0.6 1 (4.2%) 
diabetic
2.0 ± 1.0 0% DM 3.25 ± 2.05
Steatosis 2.6 ± 1.1 5 (20%) 
diabetic
NASH 3.26 ± 1.6 13 ± 8.7 23 (62%) 
diabetic
12 ± 9.0 53.8% DM 4.05 ± 2.65
ALT Control 17.6 ± 5.0 33 ± 11 22.7 ± 15.5 33 ± 11 Normal 27.3 ± 15.8
Steatosis 44.4 ± 30.0 45.5 ± 24.0
NASH 84.6 ± 58.6 75 ± 36 57.1 ± 29.3 75 ± 36 64.1 
(34.2–120)
36.5 ± 22.7
AST Control 22.8 ± 5.7 N/A 22.3 ± 11.3 N/A Normal 21.3 ± 11.9
Steatosis 31.4 ± 15.4 45.6 ± 51.9
NASH 63.4 ± 46.7 N/A 42.4 ± 18.7 N/A 46.2 
(26.8–79.8)
24.6 ± 17.5
Bile acids Total Increased Increased Increased Increased Increased No changes
Primary Increased Increased Increased Increased Increased No changes
Secondary Increased Increased Decreased N/A Increased No changes
Conjugated Increased Increased Increased Increased Increased No changes
Unconjugated N/A* Increased 
but not 
significant
No changes N/A Slightly 
increased
No changes
Compositions 
of bile acids
N/A No 
significant 
changes
Significantly 
altered
N/A N/A No changes
*N/A, not available.
Table 1. 
Dysregulation of bile acids in adults with NAFLD with characteristics of the studied subjects.
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The third different characteristic of the NASH patients in study 6 from studies 
1 to 5 is the liver injury status. The NASH patients in study 6 exhibited much lower 
ALT and AST levels than those in the NASH patients in studies 1–5, indicating that 
the NASH patients in study 6 experienced minimal liver injury, while the NASH 
patients in other studies exhibited hepatic injury or damage with the ALT and AST 
levels above the physiological values. As discussed earlier, it is well established that 
liver injury potentially can cause dysregulation of bile acids [38–42]. The differing 
liver injury statuses may provide an explanation for the discrepancy in bile acid 
alterations between the study 6 and the other five studies. Taken together, the 
characteristic variations in BMI, insulin resistance, and hepatic injury of the studied 
subjects may all contribute to the inconsistency in serum bile acid levels reported in 
those studies.
2.1.1.2 Serum bile acid profiling in children with NAFLD
There are three studies conducted with children from ages 4 to 17 years old. In 
one study with 11 healthy controls (average age 12.8 years) and 16 patients with 
NASH (average age 13.7 years), total serum bile acid levels were significantly 
elevated by threefold in children with NASH compared to healthy controls [101]. 
More specifically, the absolute concentrations of CA, CDCA, DCA, and UDCA 
were all markedly increased. The percentages of CA and DCA in the total bile acid 
pools were significantly increased, while the percentages of CDCA in the pools were 
decreased with no changes in UDCA. It is noted that both ALT and AST levels in 
patients with NASH were increased, indicating hepatic injury in those patients. The 
children with NASH also exhibited insulin resistance with an average HOMA value 
of 4.3 ± 2.8 and overweight or obese with an average BMI of 33.8 ± 7.7.
In the second study with 105 healthy controls at ages 9.3 ± 2.5 and 92 children 
with NAFLD, which were further classified into two groups based on the stages of 
fibrosis: NAFLD-F0 group at ages 10.9 ± 3.7 and F ≥ 1 group at ages 11.5 ± 1.9, total 
serum bile acids were significantly decreased from 3.6 μM in control subjects to 
1.73 μM in nonfibrotic (NAFLD-F0) patients accompanied by decreased glycine-
conjugated bile acids and slightly increased taurine-conjugated and unconjugated 
bile acids [102]. The total serum bile acids in patients with more advanced 
NAFLD with fibrosis (NAFLD-F ≥ 1) were also decreased to 2.45 μM. Comparison 
between the two NAFLD groups, the serum bile acid levels increased by 41.9% in 
the NAFLD-F ≥ 1 group. These data indicate that serum bile acid levels decrease in 
the early stage of NAFLD, followed by an increase as NAFLD progresses to fibro-
sis. No significant differences were detected in the compositions of serum total 
bile acid pools among the groups. It should be mentioned that compared with 
control subjects (BMI 18.8 ± 4.2), children in the NAFLD groups were overweight 
(BMI > 26) with significantly elevated glucose and insulin levels. In addition, 
NAFLD patients had elevated AST and ALT levels, indicating hepatic injury in 
those patients.
In a most recent third study with 35 control children at ages 12.8 ± 4.2 and 
41 NAFLD children at ages 13.7 ± 2.4, which were further divided into mild and 
moderate/severe NAFLD groups, no significant alternations in serum total, pri-
mary, and secondary bile acids were detected in children with NAFLD compared 
to control subjects [103]. Most of individual bile acid species (CA, CDCA, DCA, 
and LCA), conjugated and unconjugated bile acids, were comparable among the 
groups. Significant differences were only detected for unconjugated CDCA and 
unconjugated primary bile acids (CDCA + CA). Unconjugated CDCA and primary 
bile acids increased by 1.58-fold and 1.43-fold, respectively, in NAFLD children. 
After adjusted for age, sex, HOMA and BMI, unconjugated DCA, conjugated DCA 
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(GDCA and TDCA), and total DCA were significantly lower in NAFLD patients 
than those in the control group. Meanwhile, serum GLCA and total conjugated 
LCA (GCA + TLCA) were significantly decreased in NAFLD patients compared to 
control subjects.
The findings from the three clinical studies with detailed characteristics of the 
studied subjects are summarized in Table 2. The results from the three studies are 
largely inconsistent. In the second study with a larger size of samples, serum bile 
acid levels decrease in early stage of NAFLD and then increase during progres-
sion to fibrosis, but the levels were still below that in control subjects. In the third 
study with a medium size of samples, no significant alternations in serum total, 
primary, and secondary bile acids were detected in children with NAFLD. However, 
in the first study with smallest size of samples, total serum bile acid levels and 
compositions were significantly altered in patients with NASH compared to healthy 
controls.
Comparing the characteristics of studied subjects, the trend of bile acid altera-
tions from decrease to no changes to increase correlates with the trend of gradu-
ally increased BMI from slightly overweight (26.5 ± 3.59) to severe overweight 
(29.6 ± 5.2) to obese (33.8 ± 7.7). Such correlation indicates that NAFLD-associated 
overweight or obesity may play important roles in influencing the bile acid homeo-
stasis in children as well [85, 95, 96]. Another possible factor playing a role in bile 
acid dysregulation under the NAFLD conditions is the HOMA values, which were 
increased from 3.0 ± 3.0 in study 1 to 4.1 ± 3.2 in study 2 and 4.3 ± 2.8 in study 3. 
The differences in sample sizes of the studies certainly also contribute to the varia-
tions of bile acid levels among the studies. The sample sizes in the control groups 
ranged from 105 in study 2 to 35 in study 3 to 11 in study 1. Meanwhile, the sample 
sizes for NAFLD subjects were decreased from 92 in study 2 to 42 in study 3 to 16 in 
study 1. Taken together, serum bile acid levels were differentially altered in children 
with NAFLD. The differences in BMI, insulin resistance, and sample sizes may 
contribute to the variations of serum bile acids detected among the three studies.
2.1.2 Hepatic bile acids
There are three relevant studies investigating hepatic bile acids in patients with 
NAFLD. In the first study with 15 NASH patients and 8 control subjects, total 
hepatic bile acids were significantly increased in patients with NASH compared to 
control subjects [104]. The concentrations of individual bile acid species including 
CA, CDCA, and DCA were markedly higher in patients with NASH than those in 
the controls. It was also found that hepatic total bile acid levels were significantly 
correlated with hepatic inflammation status. Meanwhile, CDCA concentrations 
were positively correlated with fibrosis status in patients with NASH.
In a second study with liver tissues from 17 normal control subjects, 4 patients 
with simple steatosis, and 37 patients with NASH, significant alterations in hepatic 
bile acids were detected in NASH patients [105]. Hepatic CA and GDCA concentra-
tions were markedly decreased by 69 and 91%, respectively, in patients with NASH 
compared to the control subjects. In contrast, hepatic TCA, TDCA, and GCDCA 
were significantly increased by approximately three, five, and twofold in NASH 
patients, respectively. Overall, hepatic total and conjugated bile acid concentrations 
were significantly higher in patients with NASH than those in controls. On the 
other hand, unconjugated bile acids were significantly decreased in patients with 
NASH. In patients with simple steatosis, total, conjugated, and unconjugated bile 
acids were all decreased without reaching a statistical significance mainly due to a 
small sample size of the group.
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In a relevant third study with 20 control subjects and 22 diabetic patients, 
hepatic bile acid concentrations were significantly altered [106]. Among the 
22 diabetic patients, 77.7% patients had NAFLD with NAS score of 2 or above. 
Consistently, majority of patients (68%) were overweight, obese, or severe obese, 
with hypercholesterolemia being detected in 86.4% of the patients. Total hepatic 
Features Subjects Study 1 [104] Study 2 [105] Study 3 [106]
Sample 
size
Control 11 105 35
Steatosis 27 18
NASH 16 65 23
Age Control 12.8 ± 4.2 16 ± 3 9.3 ± 2.5
Steatosis 10 ± 5 10.9 ± 3.7
NASH 13.7 ± 2.4 12 ± 5 11.5 ± 1.9
BMI Control 19.2 ± 3.4 20.5 ± 4.2 18.8 ± 4.2
Steatosis 26.8 ± 3.9 26.0 ± 5.1
NASH 33.8 ± 7.7 26.5 ± 3.5 29.6 ± 5.2
Insulin Control N/A* 3.2 ± 0.6 6.9 ± 4.9
Steatosis 11.2 ± 4.8 11.0 ± 5.9
NASH N/A 12.4 ± 6.0 17.5 ± 11.4
HOMA-IR Control N/A 1.5 ± 0.3 1.3 ± 1.0
Steatosis 2.6 ± 1.8 2.6 ± 1.5
NASH 4.3 ± 2.8 3.0 ± 3.0 4.1 ± 3.2
ALT Control 19.4 ± 4.4 24 ± 28 14.0 ± 8.5
Steatosis 62 ± 20 25.5 ± 17
NASH 54.1 ± 29.7 87 ± 59 68.5 ± 42.0
AST Control 24.4 ± 11.5 25 ± 13 25 ± 8.5
Steatosis 40 ± 8 23 ± 6.7
NASH 33.9 ± 15.0 61 ± 29 40.9 ± 24.7
Bile acids Total Significantly 
increased
Significantly 
decreased
No significant 
changes
Primary Significantly 
increased
Significantly 
decreased
No significant 
changes
Secondary Significantly 
increased
Slightly decreased No significant 
changes
Conjugated N/A Significantly 
decreased
No significant 
changes
Unconjugated N/A Slightly increased No significant 
changes
Compositions of bile 
acids
Significantly 
altered
No changes No changes
*N/A, not available.
Table 2. 
Dysregulation of bile acids in children with NAFLD with characteristics of the studied subjects.
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bile acids were markedly reduced by 53% in diabetic patients compared to control 
subjects. The significant decrease in total bile acids is largely due to the marked 
reduction in conjugated bile acids. On the other hand, unconjugated bile acids were 
slightly increased by 33% without reaching a statistical significance. Among the 
conjugated bile acids, both glycine and taurine conjugated bile acids were signifi-
cantly reduced in diabetic patients. However, the reductions were more severe in 
glycine conjugated than taurine-conjugated bile acids.
In summary, no clear consensus can be reached for hepatic bile acid profiles 
in patients with NAFLD. Both increases and decreases of hepatic bile acids were 
reported. Some specific bile acid species were markedly increased, while other spe-
cies significantly decreased in the same patients. From the limited clinical studies, 
it can be concluded that hepatic bile acid homeostasis is dysregulated in patients 
with NAFLD. However, due to the complexity of bile acid regulation, variations 
in characteristics and stages of NAFLD patients, and lack of high quality clinical 
studies, it largely remains to be determined by the effects of NAFLD on hepatic bile 
acid homeostasis.
2.1.3 Fecal and urine bile acids
There are only one study investigating fecal bile acids in patients with 
NAFLD. The study has 25 healthy controls, 12 patients with steatosis, and 17 
patients with NASH [107]. Total fecal bile acid levels were significantly higher in 
patients with NASH compared to healthy controls. Meanwhile, total fecal bile acids 
also showed an increased trend in steatotic patients without reaching a statisti-
cal significance. Primary, secondary, conjugated, and unconjugated bile acid 
concentrations all exhibited a gradual increase from healthy controls to steatotic 
to NASH patients. Unconjugated primary bile acids including CA and CDCA were 
significantly increased in NASH patients compared to healthy controls, while 
unconjugated secondary bile acids were not significantly different among the three 
groups. Patients with NASH had significantly higher concentrations of conjugated 
LCA compared to patients with steatosis. In addition, a higher ratio of primary to 
secondary bile acids in patients with NASH was also detected. However, the ratio of 
total conjugated over unconjugated bile acids was not significantly different among 
the groups. Correlation analysis revealed that fecal unconjugated primary bile 
acids positively correlated with steatosis, ballooning, fibrosis, NAS scores, and liver 
injury (AST and ALT levels). The results from the study demonstrated that fecal 
disposition of bile acids was enhanced in patients with NASH. However, it remains 
to be determined that such increase in fecal disposition of bile acids is resulted from 
impairment of intestine reabsorption of bile acids or enhanced biliary excretion of 
bile acids or both.
There is only one study with 15 healthy controls and 7 NASH patients to 
investigate urine bile acid profiles in patients with NAFLD. Urine total, primary, 
secondary, conjugated, and unconjugated bile acids all exhibited a trend of increase 
without reaching a statistical significance [87]. However, individual bile acid spe-
cies including DCA, TCA, GCA, and GCDCA were significantly elevated in patients 
with NASH compared to control subjects. Consistently, total serum bile acid levels 
were also significantly increased by more than twofold in NASH patients compared 
to control subjects.
In summary, the findings from clinical studies to evaluate serum, hepatic, 
and urine bile acid profiles are inconsistent among the studies. The reasons for 
those inconsistent or even conflicting results are multiple folds. First, bile acid 
synthesis and serum concentrations fluctuate during the days and nights [108–112]. 
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Although most of the samples were collected after fasting, there was no mentioning 
on exactly when the samples were collected in the studies. Second, NAFLD rep-
resents a spectrum of pathological liver conditions from simple steatosis to NASH 
with or without fibrosis. The severity of bile acid dysregulation appears NAFLD 
stage dependent. Bile acid alterations gets worsening in patients with advanced 
stages of NAFLD, such as NASH, compared to the patients with simple steatosis 
[86, 88, 101, 102, 107]. Some studies differentiate NAFLD patients into simple 
steatosis and NASH [86, 88, 101, 102, 107], while the others [38, 87, 89, 91, 103]  
do not, which certainly influences the outcomes of the studies. Third, NAFLD is 
often associated with various metabolic conditions, especially obesity and insulin 
resistance/diabetes. It has been reported that obesity and insulin resistance directly 
impacts bile acid homeostasis [85, 95–100]. Fourth, selection of the control groups 
varies from study to study [38, 86–89, 91], which certainly contributes to the 
discrepancy of the outcomes among the studies. Finally, the sizes of samples are 
relatively small in most of the studies with individual variations potentially mask-
ing the alterations.
2.2 Altered bile acid profiles in NAFLD animal models
Several rodent models for NAFLD have been developed [113–115], includ-
ing high-fat cholesterol (HFC) and methionine- and choline-deficient (MCD) 
diet-induced or genetic deficient models, including leptin-deficient ob/ob, leptin 
receptor-deficient db/db mice, and fa/fa rats. Several preclinical studies were con-
ducted to investigate the effects of NAFLD on bile acid homeostasis using NAFLD 
mouse or rat models. In one study, NAFLD was induced in rats with HFC diet [116]. 
Total hepatic bile acids were significantly increased in rats on HFC diet for 2 weeks. 
Primary, secondary, conjugated, and unconjugated bile acid concentrations were 
all increased after 2 weeks on HFC diet. Most bile acid species remained higher in 
rats on HFC diet for 8 and 14 weeks than those on regular diet. However, the levels 
of CA and DCA species declined from their peaks at 2 weeks, while CDCA species 
persistently increased for the entire treatment. In addition, CDCA species positively 
correlated with macrovesicular steatosis score, serum ALT levels, and quantified 
fibrotic area. Among the conjugated bile acids, glycine-conjugated bile acid species 
(GCA, GCDCA, GDCA, GLCA, and GUDCA) were predominate over taurine-
conjugated bile acid species and positively correlated with macrovesicular steatosis 
score. The finding demonstrated that bile acid homeostasis is severely disrupted in 
HFC diet-induced NAFLD rats, especially the CDCA and glycine-conjugated bile 
acid species.
In another study with MCD-induced NASH mouse model, markedly increased 
serum concentrations of taurine-conjugated CA and β-muricholate (βMCA) were 
detected in mice on MCD diet for 2 or 8 weeks compared to mice on control diet, 
indicating dysregulation of serum bile acid in mice with NASH [117]. Similar 
findings were reported with ob/ob mouse model. Serum total bile acid concentra-
tions were markedly elevated by sevenfold from 1.9 ± 1.0 μM in wt control mice 
to 14.9 ± 5.4 μM in ob/ob mice [118]. In contrast to the findings from the studies 
described above, a more recent study showed that total serum bile acid concentra-
tions were not significantly different in HFD-induced NAFLD mice than mice on 
control diet [119].
Taken together, bile acid homeostasis is disrupted in NAFLD rodent models. 
Serum bile acid levels were markedly elevated in most of the studies. However, 
variations in serum bile acid concentrations exist in different NAFLD rodent 
models, may reflecting species difference between mouse and rat.
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3. Alterations in bile acid synthesis in subjects with NAFLD
3.1 Alterations in bile acid synthesis in patients with NAFLD
Primary bile acids CA and CDCA are synthesized in the liver through either the 
classical or alternative synthesis pathways. In the intestine, CA can be converted into 
secondary bile acid DCA, while CDCA is converted into secondary bile acids LCA or 
UDCA (Figure 1). Cholesterol 7α-hydroxylase (CYP7A1) is the rate-limiting enzyme 
in the classical pathway, while CYP8B1 is the rate-limiting enzyme for the produc-
tion of CA. The two rate-limiting enzymes for the alternative pathway are CYP27A1 
and CYP7B1 (Figure 1). Alterations in the expression levels of rate-limiting enzymes 
in the bile acid synthesis pathways result in dysregulation of bile acid homeostasis. 
A number of clinical studies have conducted to investigate the effects of NAFLD on 
bile acid synthesis.
3.1.1 CYP7A1
There are eight clinical studies investigating the expression of CYP7A1 in 
patients with NAFLD. Most of the studies revealed that CYP7A1 expression was 
dysregulated in patients with NAFLD. Among the eight studies, the results from 
five studies showed that the mRNA expression levels of CYP7A1 were signifi-
cantly increased in patients with NAFLD [88, 91, 94, 101, 120], indicating that 
bile acid synthesis through the classical pathway is enhanced in patients with 
NAFLD. However, in a study with 17 normal control subjects, 4 patients with 
simple steatosis, and 37 patients with NASH, CYP7A1 expression was not altered 
in patients with steatosis or NASH [105]. In another study with 6 lean healthy 
controls, 20 obese normal controls, 20 patients with simple steatosis, and 20 
patients with NASH [121], CYP7A1 mRNA expression significantly increased 
in obese normal control subjects, patients with steatosis, and NASH compared 
to healthy lean subjects. However, at the protein level, CYP7A1 expression was 
comparable in obese normal controls compared to healthy lean subjects. More 
Figure 1. 
Primary bile acids CDCA and CA are synthesized in the liver through classical (CYP7A1) and alternative 
(CYP27A1) bile acid synthesis pathways and converted into secondary bile acids LCA, UDCA, and DCA in 
the intestine.
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strikingly, CYP7A1 protein expression was markedly decreased in patients with 
steatosis and especially with NASH, indicating that bile acid synthesis through 
the classical pathway is reduced in patients with NAFLD. In a study with 78 
NAFLD patients, the subjects were divided into three groups based on the NAS 
scores, NAS 1–2, NAS 3–4, and NAS 5–8. The mRNA expression levels of CYP7A1 
were comparable among the three groups, indicating that bile acid synthesis 
through the classical pathway remains unchanged during the progression of 
NAFLD [122].
Taken together, CYP7A1 expression was largely upregulated in patients with 
NAFLD, indicating that bile acid synthesis through the classical pathway is 
enhanced in patients with NAFLD. Discrepancy in CYP7A1 mRNA and protein 
levels was noted, indicating the importance of post-transcriptional regulation of 
CYP7A1 under the NAFLD condition.
3.1.2 CYP27A1
There are three clinical studies evaluating the effects of NAFLD on the 
expression of CYP27A1. The findings from the three studies are largely inconsis-
tent. In one study, the expression levels of CYP27A1 were significantly induced in 
patients with NAFLD [101]. In contrast, a second study reported that CYP27A1 
expression was significantly decreased in patients with NAFLD compared to 
control subjects [105]. A third study showed that CYP27A1 expression was not 
altered in NAFLD subjects [121]. Therefore, it can be concluded that the effects 
of NAFLD on CYP27A1 expression are inclusive.
3.1.3 Other enzymes
There are a couple of studies investigating other enzymes involved in bile acid 
synthesis, including CYP8B1 and CYP7B1. One study reported that the expression 
levels of CYP8B1 were decreased, while CYP7B1 levels were increased in patients 
with NAFLD [105]. The other study revealed that the expression levels of CYP8B1 
were significantly increased in patients with NAFLD compared to control subjects 
[101]. Therefore, additional studies are required to determine the effects of NAFLD 
on CYP8B1 and CYP7B1 expression.
3.1.4 C4
7α-Hydroxy-4-cholesten-3-one (C4) is an intermediate of bile acid synthesis 
(Figure 1) and serves as an indicator for bile acid synthesis in vivo [123]. There 
are three studies investigating serum C4 levels in patients with NAFLD. In one 
study with 26 NAFLD patients and 16 healthy controls, the serum concentrations 
of C4 were not significantly different between the two groups, indicating that de 
novel bile acid synthesis was not changed in patients with NAFLD [38]. Consistent 
results were obtained with a second study which includes 26 healthy controls and 
32 patients with NASH. The serum C4 concentrations were not significantly altered 
in patients with NASH compared to the control subjects [90]. However, in the third 
study with 25 healthy controls, 12 patients with steatosis, and 16 patients with 
NASH, serum C4 levels were significantly elevated in patients with steatosis and 
NASH compared to healthy control subjects, suggesting that bile acid synthesis is 
enhanced in patients with NAFLD. Correlation analysis revealed that the serum C4 
concentrations were directly correlated with fecal total bile acid levels in the studied 
subjects [104]. Taken together, the serum C4 concentrations either increased or did 
not change in patients with NAFLD.
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3.2 Alterations in bile acid synthesis in NAFLD animal models
There are five studies investigating the expression of enzymes involved in bile 
acid synthesis. In one study with high fat diet (HFD)–induced NAFLD mice, the 
mRNA expression levels of Cyp7a1 and Cyp8b1 were markedly decreased compared 
to control mice on regular diet [124], indicating that de novel bile acid synthesis 
through the classical pathway is reduced in NAFLD mice. Consistent with the 
finding, a study with ob/ob mice, the expression levels of Cyp7a1 were significantly 
decreased in ob/ob mice compared to lean wt mice [118]. However, in a study with 
HFD/streptozotocin (STZ)-induced NAFLD rats, the expression levels of Cyp7a1 
were dramatically increased, while the expression levels of Cyp27a1 and Cyp7b1 
were also significantly induced in NAFLD rats compared to control rats [125]. The 
findings indicate that bile acid synthesis through both classical and alternative 
pathway is increased in HFD/STZ-induced NAFLD rats. On the other hand, in one 
study with MCD-induced simple steatotic rats, the expression levels of Cyp7a1 were 
comparable between the steatotic rats and healthy control rats [126]. Consistently, 
a study with MCD-induced NASH in mice showed that the expression levels of 
Cyp7a1 were not altered in mice with NASH compared to control mice [117]. In 
addition, the expression levels of Cyp27a1 and Cyp8b1 were not significantly 
changed in steatotic mice compared to healthy control mice. The findings indicate 
that both classical and alternative bile acid synthesis pathways are not impaired in 
MCD-induced NASH mice. In summary, the effects of NAFLD on Cyp7a1, Cyp27a1, 
and Cyp8b1 expression are inconclusive in NAFLD rodent models, which are to 
a large extent different from the findings in patients with NAFLD, especially for 
CYP7A1.
4. Alterations in bile acid transporters in subjects with NAFLD
The enterohepatic circulation of bile acids is mediated by a series of bile acid 
transporters in the liver and intestine (Figure 2). After synthesis in the liver, bile 
acids are excreted into bile through the bile salt export pump (BSEP). Majority of 
bile acids are actively transported into enterocytes by the apical sodium-dependent 
bile acid transporter (ASBT). Bile acids exit the enterocytes on the basolateral side 
via the heterodimeric organic solute transporter α and β (OSTα/β) and then return 
to the liver through the Na+/taurocholate cotransporting polypeptide (NTCP), 
completing the circulation. In the liver, other transporters are also capable of 
transport bile acids, including multidrug resistance associated protein 2 (MRP2) 
on the canalicular membrane and multidrug resistance-associated protein 3 
(MRP3), MRP4, and organic anion-transporting polypeptides (OATP1B1 and 
OATP1B3) on the basolateral membrane. It should be emphasized that biliary 
excretion through BSEP is the rate-limiting step in the circulation and bile acid 
spilling into blood is mediated mainly by MRP3 and MRP4. Alteration in bile acid 
transporter expression has significant impact on bile acid compartmenting and 
homeostasis.
4.1 Alterations in bile acid transporters in patients with NAFLD
4.1.1 BSEP
As the canalicular bile acid transporter, BSEP expression was dysregulated in 
patients with NAFLD. Three clinical studies showed that BSEP mRNA expression 
15
Dysregulation of Bile Acids in Patients with NAFLD
DOI: http://dx.doi.org/10.5772/intechopen.81474
was decreased in steatotic or NASH patients compared to control subjects  
[88, 91, 122]. A different study reported that BSEP mRNA expression levels were 
increased in patients with NASH compared to the patients with simple steatosis 
[118]. On the other hand, two studies revealed that BSEP mRNA expression was 
not altered in patients with NAFLD or diabetes compared to healthy control 
subjects [101, 106]. Finally, another study reported that BSEP mRNA levels were 
elevated in lean NAFLD patients but reduced in overweight or obese patients with 
steatosis or NASH [94], indicating that body weight of the patients influences 
the expression of BSEP under the NAFLD condition. Taken together, it can be 
cautiously concluded that BSEP expression was largely decreased in patients with 
NAFLD. The alterations BSEP expression may be influenced by the body weight 
of the patients.
4.1.2 NTCP
Three clinical studies showed that NTCP mRNA expression levels were signifi-
cantly upregulated in patients with NAFLD compared to control subjects  
[88, 101, 94]. However, a different study reported that NTCP mRNA expression 
was significantly decreased as NAFLD progressed from earlier stage (steatosis) to 
late stage (NASH) [122]. On the other hand, one study reported that the mRNA 
levels of NTCP were significantly increased in patients with NASH compared to 
patients with simple steatosis. However, at the protein level, NTCP expression was 
significantly reduced in the patients with NASH compared to patients with simple 
steatosis [127], indicating the dominance of post-transcriptional regulation of 
NTCP under the NASH condition. Another study with diabetic patients reported 
that NTCP mRNA expression levels were comparable between diabetic patients 
Figure 2. 
Enterohepatic circulation of bile acids through a series of bile acid transporters, and regulation of bile acid 
synthesis by the FXR/SHP and FGF19/FGFR4 synthesis pathway.
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and control subjects [106]. In summary, NTCP expression was likely upregulated in 
NAFLD patients with certain inconsistency.
4.1.3 MRPs
In one study with NAFLD and one study with diabetic patients, MRP2 mRNA 
expression levels were not significantly altered in NAFLD and diabetic patients com-
pared to control subjects [88, 106]. Another study reported that MRP2 mRNA expres-
sion levels were decreased as the NAFLD progressed from steatosis to NASH [122]. 
Supporting MRP2’s role in NAFLD, it was found that a polymorphism in MRP2 was 
significantly associated with NAFLD [128]. Currently, there is only one study inves-
tigating the expression levels of MRP3 in patients with NAFLD. The MRP3 mRNA 
expression levels were significantly elevated in patients with NAFLD, especially with 
NASH, compared to the healthy control subjects [94]. In another study with diabetic 
patients, MRP3 and MRP4 expression levels were not significantly altered in diabetic 
patients compared to control subjects [106]. Taken together, the results from limited 
studies suggest that MRP3 and MRP4 were upregulated in patients with NAFLD, 
while the effects of NAFLD on MRP2 expression were minimal.
4.1.4 OATPs
There is currently only one study investigating the expression of OATPs in 
patients with NAFLD. Both OATP1B1 and OATP1B3 mRNA expression levels were 
significantly upregulated in patients with NAFLD compared to control subjects 
[101]. In a different study with diabetic patients, the expression levels of OATP1B1 
were comparable in diabetic patients compared to control subjects [106]. Therefore, 
it can be cautiously concluded that OATP1B1 and OATP1b3 expression were largely 
induced in patients with NAFLD.
4.2 Alterations in bile acid transporters in NAFLD animal models
4.2.1 Bsep
Several studies have investigated the effects of NAFLD on Bsep expression in 
rodents. In one study with HFD/STZ-induced NAFLD rats, the Bsep mRNA levels 
were significantly downregulated in NAFLD rats compared to control rats [125], 
indicating reducing biliary excretion of bile acids in HFD/STZ-induced NAFLD 
rats. However, in two other studies with MCD-induced NAFLD rats and mice, the 
mRNA expression levels of Bsep were not altered in NAFLD rats or mice  
[126, 117]. Consistently, a study with obese zucker rats showed that Bsep expres-
sion was not significantly altered in obese ZR rats compared to control rats [129]. 
In another study with obese ZR rats, the expression levels of Bsep mRNA were 
significantly decreased in obese ZR rats, while Bsep protein levels detected by 
Western blot as well as immunohistochemistry were comparable between obese 
ZR rats and lean control rats [130]. In another study with ob/ob mice, the expres-
sion levels of Bsep mRNA were significantly increased in ob/ob mice compared to 
lean control mice. However, in contrast to the mRNA levels, Bsep protein levels 
were significantly decreased in ob/ob mice when compared to lean control mice 
[118]. Consistent with decreased Bsep expression in NAFLD mice, overexpression 
of Bsep increases hepatobiliary lipid secretion and reduces hepatic steatosis [131]. 
Taken together, Bsep expression was either not altered or decreased in NAFLD 
rodent models.
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4.2.2 Ntcp
Currently, there are six studies evaluating the effects of NAFLD on Ntcp 
expression in rodents. In three studies, the expression levels of Ntcp were consis-
tently decreased in animals with NAFLD compared to control animals  
[117, 125, 132]. Two studies were conducted in rats, while one study was carried 
out in mice. The common feature among the three studies is that NAFLD was 
induced by MCD for 8 weeks. In the same study [132], Ntcp expression levels were 
also significantly decreased when NAFLD was induced by HFD. On the other 
hand, another two studies with rats showed the Ntcp expression was not altered 
under the NAFLD condition [126, 130]. Different effects of NAFLD on Ntcp 
mRNA and protein expression were reported in a study with ob/ob mice [118]. 
The expression levels of Ntcp mRNA were not changed in ob/ob mice compared 
to the lean control mice. However, Ntcp protein levels were significantly lower in 
ob/ob mice than those in lean control mice. Taken together, the effects of NAFLD 
on Ntcp expression were largely consistent among the six studies, either no 
significant changes or decreased dependent on the species and methods by which 
NAFLD was induced.
4.2.3 Mrps
The effects of NAFLD on Mrp expression were extensively investigated mainly 
due to the fact that Mrps are important transporters for xenobiotics including 
drugs. Data from eight studies evaluating Mrp2 expression in NAFLD rodents are 
not consistent. Two studies with obese ZR rats reported consistent results that the 
expression levels of Mrp2 mRNA and protein were significantly downregulated 
in obese ZR rats compared to lean control rats [129, 130]. Consistent with down-
regulation of Mrp2 in obese zucker rats, Mrp2 expression levels were reduced 
in MCD-induced NAFLD rats compared to control rats on supplemented MCD 
[126]. On the other hand, other two studies showed that Mrp2 expression levels 
were not significantly altered in MCD-induced NAFLD rats or HFD/STZ-induced 
NAFLD mice compared to the control rats or mice [117, 125]. In a study with ob/
ob mice, Mrp2 expression levels were significantly increased at the mRNA level 
but decreased at the protein level [118]. In contrast, the mRNA levels of Mrp2 were 
decreased but protein levels were increased in MCD-induced NAFLD rats [132]. In a 
comprehensive study to evaluate various NAFLD models with mice and rats, Mrp2 
expression was significantly increased in athrogenic diet and MCD-induced NAFLD 
rats and all four types of NAFLD mouse models when compared to the correspond-
ing control rats or mice. At the protein level, Mrp2 expression was only increased 
in MCD-induced NAFLD rats [133]. Compared with Mrp2, the data for the effects 
of NAFLD on the expression of Mrp3 and Mrp4 are more consistent among the 
studies. Mrp3 and/or Mrp4 expression were significantly upregulated in five studies 
with NAFLD rats or mice [117, 124, 126, 118, 133]. On the other hand, another three 
studies with HFD/STZ-induced NAFLD rats or obese ZR rats reported that the 
expression levels of Mrp3 and/or Mrp4 were not altered in NAFLD or obese ZR rats 
compared to the controls [125, 129, 130].
In summary, the effects of NAFLD on Mrp2 expression were inconsistent or 
even conflicting. The discrepancy between Mrp2 mRNA and protein levels was 
also noted in the studies, indicating that post-transcriptional regulation plays an 
important role in regulating Mrp2 expression under the NAFLD condition. On the 
other hand, the expression of Mrp3 and Mrp4 was largely upregulated in NAFLD 
rodent models.
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4.2.4 Oatps
Currently, there are seven studies evaluating the effects of NAFLD on the 
expression of Oatps. The expression levels of Oatp1a1 mRNA and/or protein were 
consistently decreased in six studies [117, 118, 125, 129, 132, 133], while one study 
showed no changes [126]. There are three studies investigating Oatp1a4. In one 
study, the expression levels of Oatp1a4 were significantly reduced at both mRNA 
and protein levels in ob/ob mice compared to lean control mice [118]. In another 
study, the expression levels of Oatp1a4 mRNA were increased but its protein 
levels were decreased in various mouse and rat NAFLD models compared to the 
corresponding control mice or rats [133]. On the other hand, no alterations in 
Oatp1a4 expression were detected in MCD-induced NAFLD rats [126]. The effects 
of NAFLD on the expression of Oatp1b2 were very much consistent among the 
five studies. Oatp1b2 expression was significantly downregulated in four studies 
[117, 126, 132, 133], while no alterations in Oatp1b2 expression were detected in 
one study [125]. There are three studies investigating Oatp2b1. One study with 
ob/ob mice reported that Oatp2b1 mRNA levels were significantly upregulated in 
ob/ob mice compared to the lean control mice [118]. However, other two stud-
ies showed that Oatp2b1 was downregulated in obese ZR rats compared to lean 
control rats [129, 132]. Taken together, Oatp1a1 and Oatp1b2 were consistently 
downregulated, while the effects on Oatp1a4 and Oatp2b1 were inconsistent in 
NAFLD rodents.
5. Alterations in bile acid regulators in subjects with NAFLD
Bile acid synthesis is tightly regulated by multiple signaling pathways, mainly 
the FXR/SHP [134, 135] and FGF19/FGFR4 [136, 137] negative feedback loops 
(Figure 2). In the liver, activation of FXR by bile acids induces SHP expression, 
which in turn represses CYP7A1 expression, leading to reduced bile acid synthesis. 
In the intestine, activation of FXR by bile acids upregulates FGF19 (FGF15 in 
rodents). After entering the circulation, FGF19 binds to FGFR4 in the liver to acti-
vate the downstream signaling, which subsequently inhibits CYP7A1 expression, 
resulting in decreased bile acid synthesis. Those two negative feedback regulatory 
loops play critical roles in regulating bile acid synthesis and maintaining bile acid 
homeostasis. Impairment or dysregulation of the FXR/SHP and FGF19/FGFR4 
signaling pathways interrupts bile acid balance.
5.1 FXR/SHP signaling pathway
5.1.1 In human
Most of the human clinical studies revealed that the FXR/SHP signaling 
pathway was dysregulated in patients with NAFLD. In one study with 10 healthy 
controls, 39 steatotic, and 59 NASH patients, both FXR and SHP mRNA levels 
were significantly downregulated [94]. In two studies with 20 or 11 normal control 
subjects and 20 NAFLD or 16 NASH patients, the expression levels of FXR were 
significantly deceased in NAFLD or NASH patients compared to control subjects 
[101, 138]. However, the expression levels of SHP remain comparable between the 
control subjects and NAFLD or NASH patients, indicating that the FXR signaling 
is impaired in NAFLD or NASH patients [101, 138]. In a study with 33 children 
(19 NAFLD patients and 14 control children), the FXR protein levels were gradually 
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decreased from control subjects to steatotic to NASH patients, indicating the 
worsening of FXR signaling as NAFLD progresses [139]. Consistently, in a study 
with 20 simple steatosis and 20 NASH patients, the FXR protein expression levels 
were significantly decreased in NASH patients compared to the patients with simple 
steatosis, although at the mRNA level, FXR expression was higher in patients with 
NASH than those in patients with simple steatosis [127]. On the other hand, in one 
study with 26 controls and 32 NASH patients, no differences were detected in the 
expression of both FXR and SHP between control and NASH subjects [91]. Finally, 
one study showed gender differences in FXR expression. A significant decrease in 
FXR expression was detected in female but not male NASH patients compared to 
control subjects, while SHP expression was significantly decreased in both male and 
female with NASH [122]. In summary, most of the studies revealed a decreased or 
impaired FXR signaling in patients with NAFLD, and such impairment gets worsen-
ing as NAFLD progresses from simple steatosis to NASH.
5.1.2 In rodent NAFLD models
Inconsistent results have been reported regarding the status of FXR signaling in 
NAFLD rodent models. In two studies with HFD or fructose-induced NAFLD mice, 
the FXR expression levels were significantly reduced in NAFLD mice compared to 
control mice [124, 140]. However, SHP expression remained unchanged in fructose-
induced NAFLD mice while significantly increased in HFD-induced NAFLD mice. 
In another two studies with HFD/STZ or MCD-induced NAFLD rats, the FXR 
expression levels remained comparable between the NAFLD and control rats  
[125, 126]. Consistent with no changes in FXR expression, SHP expression was 
comparable between the two groups. In another study with ob/ob mice, FXR mRNA 
and protein were significantly increased in ob/ob mice compared to lean control 
mice, while no alterations in SHP expression was detected [118]. Finally, in a study 
with HFD-induced NAFLD mice, the FXR signaling status was investigated during 
the progression of NAFLD from simple steatosis to NASH, fibrosis, and hepatocel-
lular carcinoma (HCC) on an HFD [141]. FXR signaling was strongly activated in 
the early stage of NAFLD (simple steatosis) evidenced by strong upregulation of 
FXR target genes including Bsep, Mrp2, and ATP-binding cassette subfamily G 
member 5 (Abcg5)/Abcg8. However, as NAFLD progressed, FXR signaling gradu-
ally decreased but was still higher than that in the control mice on regular diet. 
Taken together, the inconsistent results from the NAFLD rodent models indicate 
that the effects of NAFLD on the FXR signaling pathway are dependent on the 
methods by which NAFLD is induced as well as the species (mouse or rat).
5.2 FGF19/FGFR4 signaling pathway
A large number of clinical studies have demonstrated that the FGF19 signal-
ing is dysregulated in patients with NAFLD. Serum FGF19 concentrations were 
significantly reduced in patients with simple steatosis or NASH compared to control 
subjects [88, 92, 101, 102, 139, 142–144]. The decreases in FGF19 concentrations 
were more severe in patients with NASH than the patients with steatosis, indicat-
ing the worsening of FGF19 signaling impairment as the NAFLD progresses from 
simple steatosis to NASH. On the other hand, there are two clinical studies showing 
that the fasting serum concentrations of FGF19 were not altered in patients with 
NAFLD compared to control subjects [107, 145]. Taken together, most of the clinical 
studies showed that the FGF19 signaling was reduced or impaired in patients with 
NAFLD.
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6. Conclusions
A large body of evidence from clinical as well as preclinical studies has dem-
onstrated that bile acid homeostasis is disrupted in subjects with NAFLD. The 
dysregulation of bile acids in patients with NAFLD gets worsening as the disease 
progresses from early stage simple steatosis to late stages NASH and NASH with 
fibrosis. Risk factors for NAFLD, especially obesity and insulin resistance, contrib-
ute to the dysregulation of bile acids in NAFLD patients.
Due to the complexity of bile acid regulation, small sample sizes in most of the 
clinical studies, variations in control subject selection, inherited differences in 
various rodent NAFLD models, and discrepancy in mRNA and protein levels of the 
target genes, inconsistent or even conflicting results, have been reported for serum 
and hepatic bile acid concentrations and compositions, as well as the expression lev-
els of bile acid synthesis enzymes, transporters, and regulators. However, detailed 
examination and evaluation of the results from various studies, especially consider-
ing the characteristics of the studied subjects and the quality of each study, certain 
trends on alterations in serum and hepatic bile acid levels, bile acid synthesis, and 
regulation in patients with NAFLD are emerged.
As depicted in Figure 3, serum total bile acid concentrations are increased in 
patients with NAFLD, as a result of increased CYP7A1 expression and bile acid 
synthesis, elevated hepatic bile acids, and augment of MRP3 and MRP4 expres-
sion. Increased CYP7A1 expression and bile acid synthesis in patients with NAFLD 
are mainly due to the impairment of the FXR/SHP and FGF19/FGFR4 signaling 
pathways. Limited studies on investigating fecal and urine bile acids showed 
that both fecal and urine bile acid concentrations were elevated in patients with 
NAFLD, consistent with increased serum and hepatic bile acid levels in those 
patients.
Figure 3. 
Effects of NAFLD on serum, hepatic, and fecal bile acid concentrations as well as on bile acid synthesis 
(CYP7A1), transporters (MRP3 and MRP4), and regulators (FXR, SHP, FGF19/15).
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7. Guidance for future studies
Future studies with high quality and large sample size are needed to solidify 
the trends depicted in Figure 3. The following points should be considered in the 
design of the future studies and interpretation of the findings. First, limited studies 
with children and adolescents revealed a different feature in bile acid dysregulation 
from adults with NAFLD. In contrast to the findings in adults, serum bile acid levels 
decrease in the early stage of NAFLD, followed by an increase as NAFLD progresses 
to fibrosis but the levels remain lower than those in the healthy control children. The 
effects of NAFLD on bile acid regulation appear different in children from adults. 
Second, the effects of NAFLD on bile acid homeostasis are stage dependent. No or 
mild effects of simple steatosis on bile acid regulation were detected, while signifi-
cant alterations in bile acids are mostly detected in patients with NASH. A large 
percentage of previous studies did not separate the steatotic and NASH patients in 
the test groups, which certainly complicates the analysis and interpretation of data. 
Third, as risk factors for NAFLD, obesity and insulin resistance/diabetes are often 
associated with NAFLD. It is well documented that obesity and insulin resistance 
directly cause dysregulation of bile acids. Therefore, those risk factors should be 
adjusted or matched in the control group in order to reveal the exact effects of 
NAFLD on bile acid homeostasis. Among the clinical studies reported, only one 
study was conducted with a matched control group, in which a different conclusion 
was reached that NASH has no effects on bile acid regulation [93]. Fourth, in future 
studies using NAFLD rodent models, it should be emphasized that species differ-
ences between rodents and human and even between mouse and rat exist, espe-
cially in the effects of NAFLD on bile acid transporter expression. Finally, in the 
investigation of gene expression, both mRNA and protein levels should be detected 
and quantified for the target genes. Most of the previous studies only evaluated 
the mRNA levels. However, discrepancy between the mRNA and protein levels is 
often detected in studies investigating both levels. It appears that under the NAFLD 
condition, posttranscriptional regulation plays a predominant role in regulating the 
genes involved in bile acid synthesis, transport, and regulation.
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